NEWS&EVENTS

BACK TO LIST
October 14, 2022 A CHANCE for researchers to win a registration for the EASL Congress 2023 We are close to reaching 500 patients and we would like to celebrate this milestone with all our colleagues and collaborators in the CHANCE study

Our target of recruiting 2,000 patients is still far behind, but with more active centers joining every month and the collective effort of all the centers that are already open across the world, we are certain that we will reach our goal soon.

The CHANCE Management Team is proud to announce that the center that will be recruiting the 500th patient will be featured on the EF CLIF website and throug our social media channels. In addition, EF CLIF will cover 100% of the registration fee for the winning team (up to 3 members) to attend the EASL Congress 2023 that will take place on 21–24 June 2023 in Vienna, Austria.

The Data Management Center will identify entry no. 500 and the winning team announced as soon as this information is available.


About the CHANCE study

CHANCE is a multicenter, global, observational study designed to assess the benefit of liver transplantation in patients with acute-on-chronic liver failure (ACLF) grade 2 or grade 3. This study counts with the support of the International Liver Transplantation Society (ILTS) and the European Liver and Intestine Transplant Association (ELITA) to recruit 2000 patients in 80 centers in 27 countries around the world. The primary objective of the CHANCE study is to compare 1-year graft and patient survival rates after liver transplantation in patients with ACLF grade 2 or grade 3 at the time of liver transplantation with patients with decompensation of cirrhosis without ACLF-2 or 3 and transplant-free survival of patients with ACLF-2 or 3 not listed for liver transplantation. The international nature of this study will allow for deep assessments of the potential impact of different precipitating factors of ACLF (e.g., alcohol vs. Hepatitis B virus flare), different types of liver transplantation (deceased donor vs. living donor liver transplantation) and different regional and national allocation systems on transplant outcomes. Beside these clinical objectives, the CHANCE study aims to build a repository of biological samples to explore new biomarkers to predict prognosis on the waiting list and after liver transplantation, and mechanisms of liver and extrahepatic organ recovery.

ClinicalTrials.gov Identifier: NCT04613921


BACK TO LIST